

Republic of the Philippines Department of Health **OFFICE OF THE SECRETARY**

28 October 2022

DEPARTMENT CIRCULAR No. 2022 - 0500

FOR: <u>ALL CONCERNED PROPONENTS SUCH AS HOSPITALS,</u> <u>MEDICAL SOCIETIES, PHARMACEUTICAL INDUSTRIES,</u> <u>POLICYMAKERS, PHILHEALTH, AND TO THE GENERAL</u> <u>PUBLIC</u>

SUBJECT: <u>Release of the Final Priority List of HTA Topics for 2022 that will</u> proceed to Topic Assessment

This has reference to the advisory released by the HTA Council (HTAC) and HTA Division (HTAD) on 12 September 2022, titled "Preliminary Priority List of HTA 2022 Under the General Track for Public Consultation from 12 to 26 September 2022". As a follow-through on this, the HTAD received and processed a total of 31 appeals from concerned proponents and key stakeholder groups, including hospitals, patient groups, pharmaceutical industries, and DOH programs.

Relative thereto, the HTA Philippines hereby makes public its final priority list of HTA Topics for 2022 that will proceed to Topic Assessment. Please note that the topics listed below will be assessed for possible inclusion in the Philippine National Formulary (PNF), or possible government funding, or inclusion in the benefit packages of PhilHealth.

	Final list of prioritized topics for NEW HEALTH TECHNOLOGIES						
No.	Type of Health Technology	Health Technology	Dosage form and strength	Applied Indication	Proponent		
. 1	1 Drug	Atezolizumab	60 mg/mL, 20 mL vial for intravenous (IV) infusion	Unresectable hepatocellular	Roche (Philippines)		
		Lenvatinib	4mg capsule	carcinoma (HCC)	Hi-Eisai Pharmaceuticals		
2	Drug	Atezolizumab	60 mg/mL, 20 mL vial for IV infusion	Metastatic non-small cell lung carcinoma (NSCLC)	Roche (Philippines)		
	-	Pembrolizumab	100mg/4mL (25mg/mL)		Philippine Society of		

Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila • Trunk Line 651-7800 local 1113, 1108, 1135 Direct Line: 711-9502; 711-9503 Fax: 743-1829 • URL: http://www.doh.gov.ph; e-mail: dohosec@doh.gov.ph

			solution for injection (IV infusion)		Medical Oncology Merck Sharp & Dohme (I.A.)
					LLC
3	Drug	Biphasic insulin aspart 30	100 units/mL suspension for injection in pre-filled pen	Type 2 diabetes mellitus in adults	Novo Nordisk Philippines Inc.
4	Drug	Brentuximab vedotin	50mg Powder for Concentrate for Solution for IV Infusion	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)	Takeda Healthcare Philippines
		Brexpiprazole	250mcg, 500mcg, 1mg, 2mg, 3mg, 4mg tablets		PhilHealth
5	Drug	Paroxetine	20mg film coated tablet	Major depressive disorder	DOH-Disease Prevention and Control Bureau (DOH-DPCB)
		Vortioxetine	5mg, 10mg, 15mg, 20mg tablets		PhilHealth
6	Drug	Ceftaroline fosamil	600 mg powder for concentrate for solution for injection	Community-acq uired pneumonia (CAP)	Pfizer Philippines
7	Drug	Ceftazidime/Aviba ctam	2g/500mg powder for concentrate solution	Hospital-acquire d Pneumonia (HAP), including ventilator associated pneumonia (VAP) Infections	Pfizer Philippines

.

		Ceftolozane/Tazob actam	1g/500 mg IV powder for injection		San Lazaro Hospital
8	Drug	Cilostazol	100 mg sustained release capsule	Treatment of ischemic symptoms; prevention of recurrence of cerebral infarction (excluding cardiogenic cerebral embolism)	Stroke Society of the Philippines
9	Clinical Equipment and Devices (CED)	Colonoscopy	N/A	Diagnosis of colorectal cancer as confirmatory test or procedure if found positive on fecal occult blood test	DOH-DPCB
10	Drug	Erdosteine	300 mg capsule	Treatment of chronic obstructive pulmonary disease (COPD)	OEP Philippine
11	MSP	Fecal occult blood testing	N/A	Screening tool for colorectal cancer among asymptomatic healthy adults, aged 45 years old and above	DOH-DPCB
12	MSP	Fecal immunohistochem ical test	N/A	Screening tool for colorectal cancer among asymptomatic	DOH-DPCB

		-		healthy adult, aged 45 years old and above	
13	Medical and Surgical Procedure (MSP)	High-Risk Human Papilloma Virus (HPV) Testing (DNA Test)	N/A	Early detection of cervical cancer	DOH-DPCB
14	Drug	Insulin degludec	100 units/mL pre-filled pen	Type 2 diabetes mellitus in adults	Novo Nordisk Philippines Inc.
		Japanese	Single dose of 0.5mL containing	Active immunization against Japanese Encephalitis Virus (JEV) and its complication of encephalitis among children aged 1 year and above.	DOH-DPCB
15	Vaccine	accine encephalitis vaccine	5.4 lg PFU of live attenuated JE Virus	Active immunization against Japanese Encephalitis Virus (JEV) and its complication of clinical meningitis among children aged 1 year and above.	
16	Preventive and Promotive Health (PPH)	Kiti-kiti X	l bag/25kg	Mosquito larvicide	L.H. Invention Agro-Chemical Manufacturing
17	Drug	Labetalol hydrochloride	5mg/mL (100mg/20mL) solution for injection	Management of hypertensive disorders in pregnancy	Manila East Medical Center
18	Drug	Liraglutide	6mg/ml solution for injection in	Type 2 diabetes mellitus in	Novo Nordisk

	1					
			pre-filled pen	adults	Philippines Inc.	
19	CED	Mammography	N/A	Screening of breast cancer	DOH-DPCB	
20	CED	Newborn Pulse Oximetry	N/A	Indirectly detecting hypoxemia in medically ill patients that may raise suspicion for a critical congenital heart disease (CCHD)	DOH-DPCB	
21	Drug	Drug	Palbociclib	75 mg, 100 mg, 125 mg capsule	le epidermal growth factor receptor 2	Pfizer Philippines Philippine Society of Medical Oncology
		Ribociclib	200mg film-coated tablet	metastatic breast cancer	Philippine Society of Medical Oncology	
22	Drug	Paliperidone palmitate every 3 months (PP3M)	410 mg / 1.315 mL, 546 mg / 1.75 mL, and 819 mg / 2.625 mL prefilled syringes	Schizophrenia or other primary psychotic disorders	Philippine Psychiatric Association	
23	Drug	Paroxetine	20mg film-coated tablet	Post-traumatic stress disorder	DOH-DPCB	
24	Vaccine	Pneumococcal Conjugate Vaccine -13 [PCV 13-Valent] (Adsorbed)	0.5 mL suspension for IM injection	All adults including senior citizens and patients with comorbidities/ri sk factors (Invasive pneumococcal disease) All adults	Pfizer Philippines	

.

				citizens and patients with comorbidities/ri sk factors (Pneumonia)	
25	Drug	Reteplase	10 Units Lyophilized Powder for Injection IV	Acute myocardial infarction	PhilHealth
26	Vaccine	Rotavirus vaccine	 1.5mL, Oral Suspension 2mL solution for oral administration 2.5mL, Freeze-dried Powder for Oral Suspension 	Prevention of rotavirus, the most common cause of severe gastroenteritis among children less than 1 year of age	DOH-DPCB
27	Drug	Trastuzumab emtansine	100 mg or 160 mg powder for concentrate for solution for IV infusion	Adjuvant treatment of people with HER2+ eBC with residual invasive disease after neoadjuvant treatment	Roche (Philippines)
28	MSP	Ultrasound with Alpha-fetoprotein (AFP)	N/A	Screening of patients at risk to develop hepatocellular carcinoma who have or have not progressed to cirrhosis	DOH-DPCB
29	MSP	Visualization in acetic acid	N/A	For screening of cervical cancer among women aged 30 to 65 years	DOH-DPCB

•

	Final list of prioritized topics for EXISTING HEALTH TECHNOLOGIES							
No.	Type of Health Health Technology Technology		Applied Indication	Proponent				
1	MSP	Renal replacement therapy	Chronic kidney disease	PhilHealth				
2	Vaccine	Pneumococcal conjugate vaccines	Pediatric immunization against pneumococcal infection and its complications (invasive pneumococcal disease, pneumonia, acute otitis media)	DPCB				

The topics in the final priority list will undergo HTA based on the decision criteria in the UHC Law that will determine the listing of the technology in the PNF and/or its inclusion in the benefit package of the PhilHealth or possible DOH funding.

For the timelines, please be guided by the <u>HTA Process Guide</u> and the criteria in the <u>HTA Methods</u> <u>Guide</u>. All important announcements hereon will also be disseminated via our <u>HTA website</u>, emails and social media campaigns.

For your information and guidance.

By Authority of the Secretary of Health:

ATTY. CHARADE MERCADO-GRANDE OIC-Undersecretary of Health Health Regulation Team